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Platelet production, maintenance, and clearance are tightly controlled processes indicative of platelets’ important roles in hemostasis and
thrombosis. Platelets are common targets for primary and secondary prevention of several conditions. Theyaremonitored clinically by com-
plete blood counts, specifically with measurements of platelet count (PLT) andmean platelet volume (MPV). Identifying genetic effects on
PLTandMPVcanprovidemechanistic insights intoplateletbiologyand their role indisease.Therefore,we formedtheBloodCellConsortium
(BCX) to perform a large-scale meta-analysis of Exomechip association results for PLT and MPV in 157,293 and 57,617 individuals, respec-
tively. Using the low-frequency/rare coding variant-enriched Exomechip genotyping array, we sought to identify genetic variants associated
with PLTandMPV. In addition to confirming 47 knownPLTand 20 knownMPVassociations, we identified 32 PLTand 18MPVassociations
not previously observed in the literature across the allele frequency spectrum, including rare large effect (FCER1A), low-frequency (IQGAP2,
MAP1A,LY75), andcommon (ZMIZ2, SMG6,PEAR1,ARFGAP3/PACSIN2) variants. Several variants associatedwithPLT/MPV (PEAR1,MRVI1,
PTGES3) were also associated with platelet reactivity. In concurrent BCX analyses, there was overlap of platelet-associated variants with red
(MAP1A, TMPRSS6, ZMIZ2) and white (PEAR1, ZMIZ2, LY75) blood cell traits, suggesting common regulatory pathways with shared genetic
architectureamong thesehematopoietic lineages.Our large-scaleExomechipanalyses identifiedpreviouslyundocumentedassociationswith
platelet traits and further indicate that several complex quantitative hematological, lipid, and cardiovascular traits share genetic factors.Introduction
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(MIM: 273800), and Wiskott-Aldrich syndrome (MIM:
301000), as well as common conditions such as acute
infection are characterized by abnormalities in the num-
ber, size, and/or reactivity of circulating blood platelets.
MPV has also been reported to be an independent risk fac-
tor for myocardial infarction (MI) in population-based
studies.1 Accordingly, anti-platelet medications including
aspirin and ADP/P2Y12 receptor blockers such as clopidog-
rel and GIIb/IIIa inhibitors that reduce platelet reactivity
are commonly used in the primary and secondary preven-
tion of several cardiovascular conditions, including stroke
and MI.2,3 Investigating the biological mechanisms that
govern platelet number (PLT) and size (MPV) can provide
insights into platelet development and clearance and has
the potential to enhance our understanding of human
diseases.
Genome-wide association studies (GWASs) have success-
fully identified numerous loci where variants are associ-
ated with PLT and MPV.4–13 To date, the largest GWAS of
PLT (n ¼ 66,867) and MPV (n ¼ 30,194) identified
68 distinct loci.8 Subsequent functional experiments of
several identified genes, including ARHGEF3 (MIM:
612115), DNM3 (MIM: 611445), JMJD1C (MIM: 604503),
and TPM1 (MIM: 191010), demonstrated their roles in
hematopoiesis and megakaryopoesis,8,14 as well as the
potential of human genetic association methods to iden-
tify genetic factors that functionally contribute to platelet
biology and dysfunction in disease.
Despite these successes, much of the heritability of these
traits remains unexplained.15 GWASs of PLTandMPV have
largely focused on more common (minor allele frequency
[MAF] > 0.05) genetic variation, with many of the associ-
ated markers located in intronic or intergenic regions. The
examination of rare (MAF < 0.01) and low-frequency
(MAF: 0.01–0.05) variants, particularly those in protein
coding regions, has the potential to identify previously un-
identified causal variants. Indeed, recent studies reaching
sample sizes of 31,340 individuals have identified rare to
low-frequency coding variants associated with PLT in MPL
(MIM: 159530), CD36 (MIM: 173510), and JAK2 (MIM:
147796), among others.16,17 Studies with larger sample
size are needed to further characterize the contribution of
rare and low-frequency genetic variation to PLT and MPV.
To conduct such a study of platelet-related traits, we
formed the Blood Cell Consortium (BCX) to perform a
large-scale meta-analysis of Exomechip association results
of blood cell traits. In this report, we describe results
from a meta-analysis of Exomechip association data in
157,293 and 57,617 participants for PLT and MPV, respec-
tively. The Exomechip is a custom genotyping array
enriched for rare to low-frequency coding variants; in addi-
tion, the Exomechip contains a scaffold of nonsynony-
mous variants and common SNPs obtained from the
NHGRI GWAS catalog of complex disorders and traits.
With increased sample size and use of the Exomechip,
our goal was to identify rare, low-frequency, and common
variants associated with PLT and MPV.42 The American Journal of Human Genetics 99, 40–55, July 7, 2016Material and Methods
Study Participants
The Blood Cell Consortium (BCX) was formed to identify genetic
variants associated with blood cell traits using the Exomechip gen-
otyping array. As the BCX is interested in the genetics of common
hematological measures, our collaborative group is divided into
three main working groups: RBC, WBC, and platelet.18,19 For the
platelet working group, our sample is comprised of 157,293 partic-
ipants from 26 discovery and replication cohorts of five ancestries:
European (EA), African American (AA), Hispanic, East Asian, and
South Asian. Detailed descriptions of the participating cohorts
are provided in the Tables S1–S4. All participants provided
informed consent, and all protocols were approved by the partici-
pating studies’ respective institutional review boards. In the
platelet working group, we analyzed two traits: PLT (3 109/L of
whole blood) and MPV (fL) (Table S3).Genotyping and Quality Control
Each participating study used one of the following Exomechip
genotyping arrays: Illumina ExomeChip v.1.0, Illumina
ExomeChip v.1.1_A, Illumina ExomeChip-12 v.1.1, Illumina
ExomeChip-12 v.1.2, Affymetrix Axiom Biobank Plus GSKBB1,
or Illumina HumanOmniExpress ExomeChip (Table S2). Geno-
types were called using either (1) a combination of the Illumina
GenomeStudio and zCall software or (2) the Exomechip joint call-
ing plan developed by the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) Consortium (Table S2).20 Stan-
dard quality-control criteria were applied by each study. Exclusion
criteria included: (1) sample call rates, (2) excess heterozygosity
rate, (3) Hardy-Weinberg equilibrium p values < 1 3 106, and
(4) sex mismatch. Additionally, ancestry was confirmed through
principal components or multi-dimensional scaling analyses us-
ing linkage disequilibrium (LD) pruned markers (r2 < 0.2) with
MAF> 1%. Scatterplots anchored using the 1000 Genomes Project
populations were visually inspected and ancestry outliers
excluded. We included only autosomal and X chromosome vari-
ants. All remaining variants (including monomorphic variants)
were aligned to the forward strand and alleles checked to ensure
that the correct reference allele was specified. We performed
study-specific quality control on each trait association results us-
ing EasyQC.21 We plotted variant allele frequencies from each
study against ethnicity-specific reference population allele fre-
quencies to identify allele frequency deviations and presence of
flipped alleles. After all quality-control procedures, each study
generated an indexed variant call file (VCF) for subsequent ana-
lyses that was checked for allele alignment using the checkVCF
package.Association Analysis
To assess the association between the blood cell traits and Exome-
chip variants in the BCX, we considered blood cell traits measured
in standard peripheral complete blood counts. When possible, we
excluded individuals with blood cancer, leukemia, lymphoma,
bone marrow transplant, congenital or hereditary anemia, HIV,
end-stage kidney disease, dialysis, splenectomy, and cirrhosis,
and those with extreme measurements of platelet traits. We also
excluded individuals on erythropoietin treatment as well as those
on chemotherapy. Additionally, we excluded women who were
pregnant and individuals with acute medical illness at the time
of complete blood count.
For platelet traits, we used raw values of PLT (3109/L) and MPV
(fL). In each participating study, residuals for PLT and MPV were
first calculated from linear regression models that adjusted for
age, age2, sex, study center (where applicable), and principal
components of genotype data. We then transformed these resid-
uals using the rank-based inverse normal transformation. To
confirm proper implementation of this transformation in each
cohort, a scatterplot of themedian standard error versus study-spe-
cific sample size was visually inspected for deviations using
EasyQC.21 Autosomal and X chromosome variants were then
tested for associationwith each blood cell trait using either RvTests
or RAREMETALWORKER. Within individual cohorts, we per-
formed analyses in ancestry-stratified groups: EA, AA, Hispanic,
East Asian, and South Asian. Both statistical packages generate
single variant association score summary statistics, variance-
covariance matrices containing LD relationships between variants
within a 1 MB window, and variant-specific parameters including
MAF, chromosome, position, strand, genotype call rate, and
Hardy-Weinberg equilibrium p values.Discovery Association Meta-analysis
We performed ancestry-stratified (EA and AA) and combined all
ancestry (All) meta-analyses of single variant association results
using the Cochran-Mantel-Haenszel approach implemented in
RareMETALS.22 In the multi-ancestry meta-analyses (All), we
combined individuals of EA, AA, Hispanic, South Asian, and East
Asian ancestries. We included variants in the meta-analysis if the
genotype call rate was R95%. For palindromic variants (i.e., A/T
and C/G variants), we compared allele frequencies taken across
the entire consortium in order to detect flipped alleles. We kept
variants with an allele frequency difference < 0.30 or < 0.60
for race-specific (EA and AA) or combined all ancestry
analyses, respectively.21 Heterogeneity metrics (I2 and heterogene-
ity p value) were calculated using METAL.23 Using single-variant
score statistics and variance-covariance matrices of LD estimates,
we performed two types of gene-based tests: (1) variable threshold
(VT) burden test with greatest power when all rare variants in a
gene are associated consistently with a trait24 and (2) sequence
kernel association test (SKAT)25 with better power than the burden
approach when rare variants in a gene have heterogeneous effects.
For all gene-based tests, we considered only missense, nonsense,
and splice site single-nucleotide variants (SNVs) with MAF %
1%. Similar to the single variant meta-analyses, gene-based results
were generated for each major ancestry group (EA and AA) and for
the combined multi-ancestry (All) samples.Conditional Analysis
To identify independent signals around significant associations,
we performed stepwise conditional analyses conditioning on the
most significant single variant in a 1 MB window in RareMETALS.
This procedure was repeated until there was no additional SNP
significantly associated with phenotype in each region, defined
as a p value that accounts for the number of markers tested in
each ancestry group. For discovery and conditional single
variant analyses, the threshold was: AA p < 3.03 3 107, EA p <
2.593 107, and All p< 2.203 107. For gene-based tests, the sig-
nificance threshold accounted for the number of genes tested: AA
p < 2.91 3 106, EA p < 2.90 3 106, and All p < 2.94 3 106. In
regions like chromosome 12q24 with known extended LD
structure spanning more than 1 MB, we performed a stepwise
conditional analysis in GCTA using the Montreal Heart InstituteThBiobank cohort to disentangle seven independent PLT-associated
SNVs (Table S9),26 conditioning on the most significant variant
in the region.Replication Meta-analysis
We attempted to replicate PLT and MPV associations with inde-
pendent SNVs that reached significance levels in six independent
cohorts (Figure 1, Table S4). Single variant association results of the
six independent cohorts were combined in RareMETALS. Contrib-
uting replication cohorts adhered to identical quality control and
association analysis procedures described previously for the dis-
covery phase. We combined results in EA (PLT n ¼ 19,939, MPV
n ¼ 15,519) and All (PLT n ¼ 35,436, MPV n ¼ 16,088) ethnicity
groupings (Table S4). The results of discovery and replication
phases were further combined using fixed effects inverse variance
weighted meta-analysis in METAL.23Platelet Function Exomechip
Two BCX cohorts, GeneSTAR and the Framingham Heart Study
(FHS), measured platelet aggregation in a subset of genotyped
participants. Platelet aggregation measures are described in detail
elsewhere and briefly below (Table S18).27 Both studies isolated
platelet-rich plasma from fasting blood samples and measured
platelet aggregation after addition of agonists using a four-channel
light transmission aggregometer (Bio/Data Corporation). FHS
(Offspring Exam 5) tested aggregation for periods of 4 min after
administration of ADP (0.05, 0.1, 0.5, 1.0, 3.0, 5.0, 10.0, and
15.0 mM) and 5 min after administration of epinephrine (0.01,
0.03, 0.05, 0.1, 0.5, 1.0, 3.0, 5.0, and 10.0 mM), as well as lag time(s)
to aggregation with 190 mg/mL calf skin-derived type I collagen
(Bio/Data Corporation). Threshold concentrations (EC50) were
determined as the minimal concentration of agonist required to
produce a >50% aggregation. The maximal aggregation response
(% aggregation) was also determined for each participant at each
concentration tested. GeneSTAR recorded maximal aggregation
(% aggregation) for periods of 5 min after ADP (2.0 and
10.0 mM) and 5 min after epinephrine administration (2.0 and
10.0 mM), as well as lag time(s) to aggregation with equine
tendon-derived type I collagen (1, 2, 5, and 10 mg/mL). Exomechip
genotyping, quality control, and association analyses adhered to
methods described previously for PLT and MPV analysis. We
queried independent SNVs associated with PLT (n ¼ 79) and/or
MPV (n ¼ 38) in these platelet aggregation association results
and report platelet aggregation associations with p < 0.001.Further Variant Annotation
In addition to primary analyses completed in this investigation,
we took advantage of several existing resources to annotate our
associated SNVs. Associated variants were cross-referenced with
Combined Annotation Dependent Depletion (CADD) scores for
Exomechip.28 The Global Lipids Genetics Consortium (GLGC),
the CARDIoGRAMExome Consortium, andMyocardial Infarction
Genetics Consortium have each performed independent Exome-
chip analysis of lipids traits and coronary heart disease
(CHD).29,30 The CHD phenotype reflected a composite endpoint
that includedMI, CHD, coronary artery bypass graft, and hospital-
ized angina, among others.29 Similar to the platelet aggregation
lookups, we queried our list of PLT- and/or MPV-associated SNVs
against their Exomechip association results for lipids and CHD.
We report lipid and CHD associations with p < 0.0001. From a
curated collection of more than 100 separate expressione American Journal of Human Genetics 99, 40–55, July 7, 2016 43
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Discovery Single Variant and Gene-Based Meta-Analysis 
RareMETALS v5.9
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Quality Control with EasyQC v8.6
Proper trait transformaons
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PLT Replicaon
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MPV Replicaon
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Figure 1. Study Design and Flow
Individual study-level association analyses
were performed using RareMetalWorker or
RVTests. To perform quality control of in-
dividual study association results, we
used EasyQC v.8.6 to ensure proper trait
transformations, to assess allele frequency
discrepancies, and to evaluate other met-
rics. We then combined results in meta-
analysis with RareMETALS v5.9 in three
groups: African ancestry (AA), European
ancestry (EA), and combined all five (AA,
EA, Hispanic-Latino, East Asian, South
Asian) ancestries (All). Independent
variants identified by conditional analysis
in RareMETALS with a p value less than
the threshold corrected for multiple
testing (All, p < 2.20 3 107; EA, p <
2.59 3 107; AA, p < 3.03 3 107) were
carried forward for replication. Markers
showed replication if they had p < 0.05
in the same direction of effect in the repli-
cation analyses. Associated markers were
further annotated using various resources:
(1) concurrent BCX Exomechip analyses
of RBC and WBC traits, (2) on-going
Exomechip analyses of platelet aggrega-
tion, quantitative lipids, and coronary
heart disease (CHD) traits, (3) severity
prediction by CADD, (4) an internal data-
base of reported eQTL results, and (5)
platelet RNA-seq data.quantitative trait loci (eQTL) datasets, we conducted a more
focused query of whether platelet loci were also associated with
transcript expression in blood, arterial, and adipose-related tissues.
A general overview of a subset of >50 eQTL studies has been pub-
lished (Supplemental Data).31 Separately, we queried transcripts in
loci corresponding to previously unreported associated variants
and/or marginally associated variants showing further evidence
of association in our replication analyses to assess their platelet
expression levels using the largest platelet RNA-seq dataset to
date (n ¼ 32 patients with MI).32Results
Discovery Meta-Analysis
In our discovery phase, we performed a meta-analysis
of the associations of 246,925 single-nucleotide variants
(SNVs) with PLT and MPV in 131,857 and 41,529 in-
dividuals, respectively (Figures 1, S1, and S2; Tables S1–
S4). After the initial meta-analyses, we ran conditional44 The American Journal of Human Genetics 99, 40–55, July 7, 2016analyses to identify independent
loci and found 79 independent PLT
and 38 independent MPV SNVs
(Tables 1, 2, and S5–S8). One associa-
tion, rs12692566 in LY75-CD302,
with PLT in EA did not surpass the
initial discovery statistical signifi-
cance threshold but surpassed the
threshold when conditioned onnearby rs78446341 (p ¼ 2.48 3 107). There were no asso-
ciations unique to the AA ancestry group, which had a
limited sample size (Tables S10 and S11). Single variant
meta-analysis results for each ancestry grouping that met
our significance thresholds are available in the Supplement
(Tables S10 and S11). Additionally, full discovery meta-
analysis results are available online (Web Resources).
Of these independently associated single variants, 32 PLT
and 18 MPV variants were in loci not previously reported
(Tables 1 and 2). Of these 32 PLT loci, 4 had previously
been identified as MPV loci (Table 1), and 10 of the 18 MPV
loci had previously been identified with PLT (Table 2).8,9,17
Of the independent loci in our study, 23 SNVs showed asso-
ciationwithbothPLTandMPV(Table3, Figure2).Allbutone
(rs6136489 intergenic to SIRPA [MIM: 602461] and
LOC727993) had opposite directions of effect for PLT
andMPV. Additionally, the observed effect sizes for PLT and
MPVdisplayed strong negative correlations (Figure 2), indic-
ative of the strong negative correlation between these traits.
Table 1. Previously Unreported Associations with PLT
rsID Ref/Alt Function Gene
European Ancestry (EA) Combined All Ancestry (All)
Discovery (n ¼ 108,598) Replication (n ¼ 19,939) Combined Discovery (n ¼ 131,857) Replication (n ¼ 25,436) Combined
EAF Beta p Value Beta p Value p Value EAF Beta p Value Beta p Value p Value
rs3091242 C/T intron TMEM50A 0.54 0.026 9.68 3 108 0.017 0.124 3.85 3 108 0.50 0.02 1.03 3 105 0.0084 0.390 1.24 3 105
rs12566888 G/T intron PEAR1* 0.094 0.040 1.42 3 107 0.061 1.26 3 103 1.17 3 109 0.16 0.034 2.09 3 108 0.047 4.31 3 104 5.71 3 1011
rs200731779 C/G missense FCER1A 1.5 3 105 2.96 2.48 3 107 NA NA 2.48 3 107 1.2 3 105 2.96 2.48 3 107 NA NA 2.48 3 107
rs6734238 A/G intergenic IL1F10/IL1RN 0.41 0.022 9.55 3 106 0.0075 0.487 1.64 3 105 0.41 0.026 7.19 3 109 0.015 0.117 3.77 3 109
rs12692566a C/A missense LY75-CD302* 0.82 0.029 9.19 3 107 0.042 2.50 3 103 1.23 3 108 0.83 0.026 2.27 3 106 0.05 7.84 3 105 3.65 3 109
rs78446341 G/A missense LY75-CD302* 0.02 0.092 4.16 3 109 0.14 5.01 3 105 1.98 3 1012 0.018 0.094 3.06 3 1010 0.13 9.23 3 105 1.97 3 1013
rs56106611b T/G missense KALRN* 0.012 0.11 3.51 3 108 0.11 7.14 3 103 8.51 3 1010 0.01 0.11 8.59 3 108 0.11 7.37 3 103 2.14 3 109
rs1470579 A/C intron IGF2BP2 0.32 0.028 1.08 3 107 0.0073 0.562 2.82 3 107 0.38 0.023 6.07 3 107 0.012 0.272 5.15 3 107
rs1126673 C/T ncRNA LOC100507053 0.69 0.026 6.38 3 108 0.019 9.63 3 102 1.81 3 108 0.71 0.025 1.87 3 108 0.014 0.168 1.12 3 108
rs1473247b T/C intron RNF145* 0.27 0.029 3.01 3 108 0.022 8.32 3 102 7.28 3 109 0.32 0.026 1.32 3 108 0.025 1.85 3 102 7.66 3 1010
rs2256183 A/G intron MICA 0.56 0.03 6.78 3 107 0.022 0.104 2.60 3 106 0.59 0.028 2.13 3 107 0.011 0.389 3.20 3 107
rs1050331 T/G 30 UTR ZMIZ2 0.47 0.037 1.32 3 1015 0.036 5.80 3 104 3.28 3 1018 0.48 0.035 3.09 3 1017 0.031 8.80 3 104 1.26 3 1019
rs755109 T/C intron HEMGN 0.37 0.028 2.87 3 109 0.039 6.84 3 104 1.17 3 1011 0.34 0.028 9.03 3 1011 0.044 2.18 3 105 2.59 3 1014
rs2068888 G/A nearGene-3 EXOC6 0.45 0.023 2.81 3 107 0.012 0.266 2.47 3 107 0.44 0.022 1.19 3 107 0.012 0.212 8.61 3 108
rs3794153 C/G missense ST5 0.45 0.027 7.28 3 109 0.026 1.53 3 102 3.57 3 1010 0.40 0.027 2.19 3 109 0.023 2.47 3 102 1.74 3 1010
rs174583 C/T intron FADS2 0.34 0.031 8.79 3 109 0.048 1.22 3 104 1.03 3 1011 0.34 0.028 4.72 3 109 0.042 1.10 3 104 4.42 3 1012
rs45535039 T/C 30 UTR CCDC153 0.28 0.04 4.02 3 1010 0.071 5.31 3 102 8.48 3 1011 0.28 0.04 2.5 3 1012 0.056 8.56 3 102 6.25 3 1013
rs11616188 G/A nearGene3 LTBR 0.42 0.025 1.26 3 108 0.031 3.59 3 103 1.81 3 1010 0.37 0.025 7.57 3 109 0.033 1.07 3 103 4.20 3 1011
rs10506328b A/C intron NFE2 0.64 0.033 5.63 3 1011 0.06 5.88 3 108 2.01 3 1016 0.69 0.038 3.79 3 1015 0.059 2.33 3 108 2.73 3 1021
rs2279574 C/A missense DUSP6 0.54 0.023 2.47 3 107 0.0082 0.442 4.28 3 107 0.50 0.021 1.57 3 107 0.006 0.531 4.04 3 107
rs61745424 G/A missense CUX2 0.025 0.064 2.36 3 106 0.085 6.79 3 103 6.49 3 108 0.023 0.068 1.37 3 107 0.073 1.43 3 102 6.30 3 109
rs2784521 A/G nearGene-5 DDHD1 0.83 0.025 1.62 3 105 0.0096 0.486 2.24 3 105 0.76 0.028 2.92 3 108 0.01 0.363 5.56 3 108
rs55707100 C/T missense MAP1A* 0.032 0.095 7.03 3 1014 0.073 3.87 3 102 9.53 3 1015 0.028 0.092 6.85 3 1014 0.082 1.62 3 102 3.77 3 1015
rs10852932 G/T intron SMG6* 0.36 0.024 1.82 3 106 0.042 8.93 3 104 1.42 3 108 0.39 0.025 4.79 3 108 0.036 6.99 3 104 2.15 3 1010
rs76066357 G/C missense ITGA2B* 0.014 0.17 6.92 3 1016 0.19 2.88 3 105 1.05 3 1019 0.013 0.16 1.92 3 1015 0.18 6.00 3 105 5.78 3 1019
rs1801689 A/C missense APOH* 0.036 0.083 6.34 3 1012 0.13 2.44 3 105 1.82 3 1015 0.032 0.090 8.64 3 1015 0.12 2.03 3 105 1.57 3 1018
rs892055 A/G missense RASGRP4 0.34 0.029 5.30 3 1010 0.018 9.87 3 102 2.01 3 1010 0.38 0.025 3.49 3 109 0.017 8.13 3 102 9.96 3 1010
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46 The American Journal of Human Genetics 99, 40–55, July 7, 2016Associated variants ranged in allele frequency and
included rare, low-frequency, and common SNVs. Most
of the previously unreported associations were with com-
mon variants (PLT n ¼ 25, MPV n ¼ 15), although associ-
ations with low-frequency (PLT n¼ 6, MPV n¼ 2) and rare
(PLT n ¼ 1, MPV n ¼ 1) variants were observed. Rare (PLT
n ¼ 6, MPV n ¼ 1) SNVs associated with PLT and MPV had
larger effects compared to common and low-frequency
SNVs (Tables 1, 2, and S5–S8). A largemajority of associated
SNVs did not exhibit heterogeneous effects; however, one
previously unreported association with MRVI1 and a few
known associated loci (e.g., MYL2/SH2B3/ATXN2,
ARHGEF3, WDR66/HPD, and JAK2) did show moderate
to substantial heterogeneity across discovery studies (Table
S23). Gene-based tests of missense, nonsense, and splice-
site rare variants that found significant results largely
reflected rare and low-frequency single variant results,
with variants in TUBB1 (MIM: 612901), JAK2, LY75
(MIM: 604524), IQGAP2 (MIM: 605401), and FCER1A
(MIM: 147140) showing associations (Tables S12 and S13).
Replication Meta-Analysis
We attempted to replicate our associations in six indepen-
dent cohorts (PLT n ¼ 25,436, MPV n ¼ 16,088) (Figure 1,
Table S4). Of the loci not previously associated, 20/32 PLT
and 11/18 MPV variants showed evidence of replication
with p < 0.05 and the same direction of effect (Tables 1
and 2). In addition to the significant SNVs in our discovery
analysis, we carried forward 13 PLT and 10 MPV sub-
threshold variants that approached discovery significance
thresholds with p values ranging from 2.47 3 107 to
1.99 3 106 (Tables S14 and S15). Of these, 7/13 PLT and
4/10 MPV showed associations in same direction of effect
with p < 0.05 and surpassed significance thresholds
when discovery and replication results were combined
(Tables S14 and S15).
Intersection with Other Cardiovascular and Blood
Traits
The BCX also completed analyses of RBC and WBC traits,
so we cross-referenced our list of PLT- and MPV-associated
SNVs with the results of the other blood cell traits.18,19 Of
our replicated platelet loci previously unreported in the
literature, six SNVs in TMPRSS6 (MIM: 609862), MAP1A
(MIM: 600178), PNPLA3 (MIM: 609567), FADS2 (MIM:
606149), TMEM50A (MIM: 605348), and ZMIZ2 (MIM:
611196) showed association with RBC-related traits (p <
0.0001) (Table 4). Similarly, five replicated platelet SNVs
previously unreported in the literature in PEAR1 (MIM:
610278), CD33 (MIM: 159590), SIRPA, ZMIZ2, and LY75
showed association with WBC-related traits (p < 0.0001)
(Table 4). To explore possible shared genetic associations
of platelet size/number with platelet reactivity, we exam-
ined the association of PLT/MPV-associated SNVs with
platelet reactivity to collagen, epinephrine, and ADP
in GeneSTAR and FHS. Eight SNVs associated with PLT
and/or MPV were also associated with platelet reactivity
Table 2. Previously Unreported Associations with MPV
rsID Ref/Alt Function Gene
European Ancestry (EA) Combined All Ancestry (All)
Discovery (n ¼ 34,021) Replication (n ¼ 15,519) Combined Discovery (n ¼ 41,529) Replication (n ¼ 16,088) Combined
EAF Beta p Value Beta p Value p Value EAF Beta p Value Beta p Value p Value
rs6687605 T/C missense LDLRAP1* 0.53 0.046 8.27 3 1012 0.025 3.74 3 102 1.80 3 109 0.51 0.046 9.92 3 1011 0.024 3.58 3 102 3.80 3 1011
rs56043070a G/A splice GCSAML* 0.069 0.094 1.30 3 109 0.19 4.48 3 1016 1.12 3 1021 0.064 0.092 2.25 3 1010 0.19 3.66 3 1016 2.42 3 1022
rs1339847a G/A missense TRIM58 0.10 0.10 1.47 3 1013 0.037 5.44 3 102 9.31 3 1013 0.10 0.11 2.18 3 1017 0.032 9.77 3 102 1.06 3 1015
rs34968964a G/C missense IQGAP2 0.0049 0.32 7.65 3 109 0.12 9.18 3 102 1.99 3 108 0.004 0.32 2.11 3 109 0.11 0.106 8.18 3 109
rs34950321a C/T missense IQGAP2* 0.018 0.18 7.80 3 1010 0.14 1.49 3 103 6.03 3 1012 0.016 0.17 2.61 3 109 0.14 1.59 3 103 1.86 3 1011
rs34592828a G/A missense IQGAP2* 0.037 0.22 1.72 3 1027 0.16 2.73 3 109 1.61 3 1034 0.032 0.23 1.68 3 1031 0.16 2.95 3 109 2.98 3 1038
rs1012899a G/A missense LRRC16A 0.77 0.051 1.40 3 107 0.012 0.417 1.24 3 106 0.77 0.042 1.32 3 106 0.016 0.273 2.50 3 106
rs664370 A/G missense PXT1* 0.30 0.034 8.03 3 105 0.025 5.61 3 102 1.39 3 105 0.35 0.042 5.77 3 108 0.028 2.78 3 102 7.23 3 109
rs2343596a C/A intron ZFPM2 0.31 0.062 2.02 3 1013 0.012 0.357 3.32 3 1011 0.38 0.052 1.59 3 1011 0.012 0.339 4.35 3 1010
rs55895668a T/C missense PLEC 0.43 0.042 5.94 3 107 0.013 0.350 2.19 3 106 0.47 0.041 1.23 3 107 0.011 0.409 5.97 3 107
rs4909945 T/C missense MRVI1* 0.68 0.048 1.25 3 108 0.035 8.41 3 103 5.19 3 1010 0.71 0.041 3.96 3 107 0.035 7.42 3 103 1.06 3 108
rs11125 A/T missense LGALS3 0.078 0.091 1.55 3 108 0.037 0.117 2.76 3 108 0.07 0.09 4.22 3 109 0.037 0.117 7.21 3 109
rs2010875a C/T missense PLEKHO2* 0.14 0.076 1.33 3 107 0.042 1.62 3 102 2.10 3 108 0.15 0.063 3.01 3 107 0.042 1.62 3 102 2.43 3 108
rs10512472a T/C missense SLFN14* 0.18 0.059 1.37 3 108 0.059 1.96 3 104 1.12 3 1011 0.18 0.058 3.15 3 1010 0.059 1.20 3 104 1.67 3 1013
rs35385129 C/A missense PVR* 0.16 0.058 6.24 3 108 0.044 7.36 3 103 2.01 3 109 0.15 0.055 3.00 3 108 0.043 7.13 3 103 8.79 3 1010
rs2243603 C/G missense SIRPB1 0.77 0.044 5.89 3 106 0.077 0.167 2.62 3 106 0.79 0.049 4.58 3 108 0.088 7.78 3 102 1.25 3 108
rs1018448 A/C missense ARFGAP3* 0.55 0.056 1.13 3 1012 0.051 1.78 3 105 1.04 3 1016 0.60 0.055 1.52 3 1013 0.05 2.16 3 105 1.68 3 1017
rs1997715 G/A 30 UTR ZXDB* 0.26 0.048 1.93 3 109 0.084 5.83 3 102 4.26 3 1010 0.35 0.04 4.58 3 108 0.08 3.99 3 102 8.88 3 109
We show variants in previously unreported MPV loci (n ¼ 18) and retained after conditional analyses in European ancestry (EA) (p < 2.59 3 107) and all ancestry (All) (p < 2.20 3 107) analyses. Associations in African
ancestry (AA) had previously been reported in the literature (Table S11). Asterisk (*) indicates variants (11/18) that showed evidence of replication (p < 0.05, same direction of effect). If multiple genes/transcripts were
annotated to a variant, the transcript more expressed in Eicher et al.32 (Table S22) was selected. Full results and annotations are available in Table S7. Abbreviations are as follows: MPV, mean platelet volume; PLT, platelet
count; REF, reference allele; ALT, alternate allele; EAF, effect allele frequency.
aPrevious association with PLT.
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Table 3. Variants Associated with Both PLT and MPV
rsID Gene PLT MPV
rs12566888 PEAR1 [ Y
rs1668873 TMCC2 [ Y
rs56043070 GCSAML Y [
rs12485738 ARHGEF3 [ Y
rs56106611 KALRN [ Y
rs34592828 IQGAP2 Y [
rs1012899 LRRC16A Y [
rs342293 PIK3CG Y [
rs2343596 ZFPM2 Y [
rs10761731 JMJD1C [ Y
rs11602954 BET1L [ Y
rs10506328 NFE2 [ Y
rs2958154 PTGES3 Y [
rs7961894 WDR66 Y [
rs1465788 ZFP36L1 [ Y
rs2297067 EXOC3L4 [ Y
rs2138852 TAOK1 Y [
rs10512472 SLFN14 [ Y
rs11082304 CABLES1 Y [
rs6136489* SIRPA/LOC727993 Y Y
rs41303899 TUBB1 Y [
rs6070697 TUBB1 [ Y
rs1018448 ARFGAP3 Y [
All variants listed here showed association with both PLT and MPV in the oppo-
site direction of effect as indicated by the arrows, except for rs6136489 (de-
noted by asterisk), which showed association with decreased PLT and
decreased MPV. Abbreviations are as follows: PLT, platelet count; MPV,
mean platelet volume.(p < 0.001) (Tables 5, S18, and S19). The most strongly
associated SNVs were located in genes implicated with
platelet reactivity in prior GWASs, including PEAR1,
MRVI1 (MIM: 604673), JMJD1C, and PIK3CG (MIM:
601232).27 However, we did observe new suggestive rela-
tionships between platelet reactivity and SNVs in PTGES
(MIM: 607061), LINC00523, and RASGRP4 (MIM:
607320) (Table 5).
In addition to examining possibly shared genetic asso-
ciations with blood cell-specific traits, we queried our list
of associated platelet SNVs against independent Exome-
chip genotyping efforts in lipids and CHD by the
GLGC, CARDIoGRAM Exome Consortium, and My-
ocardial Infarction Genetics Consortium Exomechip
studies.29,30 Numerous platelet-associated SNVs (n ¼
37), including those in GCKR (MIM: 600842), FADS1
(MIM: 606148), FADS2, MAP1A, APOH (MIM: 138700),
and JMJD1C, showed association with one or more lipids
traits (p < 0.0001) (Table S20). Far fewer (n ¼ 4; MYL248 The American Journal of Human Genetics 99, 40–55, July 7, 2016[MIM: 160781], SH2B3 [MIM: 605093], BRAP [MIM:
604986], APOH) showed association with CHD (p <
0.0001) (Table S20).Annotation of Associated Variants
We used various resources to annotate our platelet-associ-
ated variants. First, we used CADD to predict the putative
functional severity of associated variants.28 As expected,
rare and low-frequency coding SNVs were predicted to be
more severe than common, non-coding variation (Tables
1, 2, and S5–S8). To assess potential impact on gene expres-
sion, we queried our list of platelet-associated SNVs against
a collection of results from existing eQTL datasets.31 Many
(n ¼ 67) platelet-associated SNVs were also associated with
gene expression in blood, arterial, or adipose tissues (Table
S21). These included the reported trans-eQTL rs12485738
in ARHGEF3 with several platelet-related transcript targets
(e.g., GP1BA, GP6, ITGA2B, MPL, TUBB1, and VWF),33 as
well as eQTLs in newly identified PLT/MPV loci (e.g.,
rs1018448 with ARFGAP3/PACSIN2, rs1050331 with
ZMIZ2, and rs174546 with FADS1/FADS2/TMEM258
expression). Using platelet RNA-seq data from 32 subjects
with MI, we found that almost all of the genes closest to
our previously unreported associated SNVs or marginal
SNVs with evidence of replication were expressed in plate-
lets, indicating the feasibility of potential functional roles
in the relevant target cell type (Table S22).32Discussion
Here, we present a large-scale meta-analysis of Exomechip
association data with two clinical platelet measurements,
PLTandMPV. By combining Exomechip association results
in 157,293 and 57,617 participants, respectively, we de-
tected numerous associations with rare, low-frequency,
and common variants. There was substantial overlap of
our platelet associations with concurrent Exomechip asso-
ciation findings for RBC and WBC traits, indicating shared
genetic influence on regulatory and functional mecha-
nisms among the three different blood cell lineages.18,19
More surprisingly, we observed shared associations of
platelet and lipids loci. The identification of shared blood
cell and lipids associations as well as identifying genes
with entirely new associations reveals candidates for
further examination in order to elucidate the mechanisms
underlying platelet development and function.Using Exomechip to Identify Previously Unreported
Genetic Associations
Using the Exomechip that has an emphasis on rare and
infrequent coding variation, we found associations with
variants that ranged from common to rare in allele
frequency. We attempted to replicate independent associa-
tions, although our replication cohorts were underpow-
ered to associations of rare variants. To inform our replica-
tion criteria, we conducted a power analysis by using a
Figure 2. Shared PLT and MPV Genetic Associations
(A) Comparing PLTandMPVeffects sizes (r¼0.84) in European ancestry (EA) analyses of all identified SNVs identified (n¼ 124). Exam-
ined SNPs include all those from Tables 1, 2, S5–S9, S14, and S15.
(B) 56 independent SNVs showed association to PLT only, and 15 independent SNVs were associated with MPV only. 23 independent
SNVs were associated with both PLT and MPV. Named genes indicate that the association was not previously reported in the literature.sample size of 20,000 and considering multiple combina-
tions of allele frequencies and effect sizes. Based on allele
frequency and effect size, our most difficult to replicate
variant was rs56106611 (MAF ¼ 0.012, Beta ¼ 0.11). How-
ever, we still had approximately 80% power to detect this
association in the replication stage. Despite this, replica-
tion of extremely rare variants remains a challenge. For
example, there were associations with rare coding variants
with large effect sizes in FCER1A, MPL, JAK2, SH2B3,
TUBB1, and IQGAP2.16,17 The overall effect size of these
rare variants must be validated in independent studies.
The PLT-associated and predicted deleterious variant
rs200731779 in FCER1A (p.Leu114Val) had a large effect
(b ¼ 2.96) in discovery analyses, but could not be repli-
cated in available samples due to its extremely rare allele
frequency (MAF ¼ 1.48 3 105 in EA). The affected amino
acid is extracellularly positioned near the interface of two
Ig-like domains, an area of the protein critical for FC-IgE
interaction as shown through its crystal structure,
biochemical data, and mutagenesis studies.34–37 Other var-
iants in FCER1A, a subunit of the allergy response IgE re-
ceptor and basophil differentiation factor, have previously
been associated with IgE levels and monocyte counts.38,39
Increased platelet activation has been postulated to
contribute to or be a consequence of allergic and inflam-
matory responses.40 Our association of rare deleterious
variation in FCER1A to reduced PLT provides a further
link between platelet biology and allergy response.
Although SNVs in IQGAP2 have previously been associ-
ated with PLT, we detected independent IQGAP2 low-fre-
quency and rare missense variants associated with
increased MPV (Table 2, Figures S3 and S4).8,17 Located
proximal to thrombin receptor F2R (MIM: 187930),
IQGAP2 functions in the cytoskeletal dynamics in
response to thrombin-induced platelet aggregation.41 WeThdid not observe IQGAP2 associations with platelet aggrega-
tion, which may be due to the rare/low-frequency nature
of the SNVs and the absence of thrombin-induced aggrega-
tion data in the available cohorts. Nonetheless, the associ-
ations of rare and low-frequency variants in IQGAP2
further strengthen its contribution to platelet biology. In
addition to IQGAP2, we observed other low-frequency as-
sociations, including nonsynonymous coding variants in
ITGA2B (MIM: 607759), LY75, MAP1A, and APOH. The
SNV rs76066357 in ITGA2B, a gene implicated in Glanz-
mann’s thrombasthenia (MIM: 273800), was associated
with decreased PLT (Table 1). Moreover, ITGA2B codes for
the platelet glycoprotein alpha-IIb, which is part of the
target receptor of GIIb/IIIa inhibitors (e.g., eptifibatide
and abciximab) used in the acute management of acute
coronary syndromes. Although ClinVar lists rs76066357
as pathogenic (ID: 216944) with limited evidence,
rs76066357 is a non-rare, predicted benign variant that
contributes to population variability in PLT in our study
as opposed to a severe Mendelian disorder of platelet reac-
tivity.42 Previous studies do suggest a potential role for
variants in ITGA2B and ITGB3 (MIM: 173470) leading to
thrombocytopenia as well as abnormalities in platelet reac-
tivity.43
In addition to rare and low-frequency variant associa-
tions, we detected previously unreported associations for
PLT and MPV at 25 and 15 common loci, respectively.
For example, a common missense SNV rs1018489 in
ARFGAP3 (MIM: 612439) showed association with
decreased PLT and increased MPV. This variant is an
eQTL for both ARFGAP3 and neighboring gene PACSIN2
(MIM: 604960) in blood tissues (Table S21, Figures S5
and S6). Although the possible role of the androgen recep-
tor (AR) gene target and cellular secretory factor ARFGAP3
is unknown in platelets,44–46 PACSIN2 functions in thee American Journal of Human Genetics 99, 40–55, July 7, 2016 49
Table 4. Intersection of Platelet-Associated Variants with RBC and WBC Traits
SNP MarkerName Gene PLT Trait Other Blood Cell
rs855791 chr22: 37,462,936 TMPRSS6 Y MCH, MCV, HGB MCHC, HCT [
rs855791 chr22: 37,462,936 TMPRSS6 Y RDW Y
rs55707100 chr15: 43,820,717 MAP1A [ HGB, MCH, HCT, MCHC Y
rs174583 chr11: 61,609,750 FADS2 [ RDW Y
rs174583 chr11: 61,609,750 FADS2 [ HGB, RBC, HCT, MCHC [
rs738409 chr22: 44,324,727 PNPLA3 Y HCT, HGB [
rs3091242 chr1: 25,674,785 TMEM50A Y RDW [
rs1050331 chr7: 44,808,091 ZMIZ2 [ MCH, MCV Y
rs1050331 chr7: 44,808,091 ZMIZ2 [ WBC [
rs6734238a chr2: 113,841,030 IL1F10/IL1RN [ MCH Y
rs6734238a chr2: 113,841,030 IL1F10/IL1RN [ WBC, NEU [
rs12566888 chr1: 156,869,047 PEAR1 [ WBC, NEU, MON Y
rs3865444 chr19: 51,727,962 CD33 Y WBC Y
rs6136489 chr20: 1,923,734 SIRPA/LOC727993 Y WBC, LYM Y
rs2256183a chr6: 31,380,529 MICA [ BAS [
rs12692566 chr2: 160,676,427 LY75-CD302 Y WBC Y
We cross-referenced novel variants associated with platelet count (PLT) and/or mean platelet volume (MPV) in RBC andWBC association analyses in the Blood Cell
Consortium (BCX). Here, we show RBC/WBC-associated platelet variants with p < 0.0001. Full details of RBC/WBC associations are shown in Tables S16 and S17.
Arrows denote direction of effect for the platelet and other blood cell trait(s). Abbreviations are as follows: BCX, Blood Cell Consortium; RBC, red blood cell; WBC,
white blood cell; PLT, platelet count; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume; HGB, hemoglobin; MCHC, mean corpuscular he-
moglobin concentration; HCT, hematocrit; RDW, red blood cell distribution width; PLT, platelet count; NEU, neutrophil; MON,monocyte; LYM, lymphocyte; BAS,
basophil.
aMarker not replicated in platelet analyses.formation of the megakaryocyte demarcation membrane
system during platelet production through interactions
with FlnA.47 Genetic variation that influences PACSIN2
expression may hinder the formation of the megakaryo-
cyte demarcation membrane system and lead to the pro-
duction of fewer but larger and potentially more reactive
platelets. We also observed several other novel associations
with common variants, including those in SMG6 (MIM:
610963), a mediator of embryonic stem cell differentiation
through nonsense-mediated decay, and LY75, an endocy-
totic immunity-related receptor highly expressed on den-
dritic cells where it is involved in recognition of apoptotic
and necrotic cells.48–50
Overlap with Other Platelet and Blood Cell Traits
There was substantial overlap of variants associated with
both PLTandMPV (n¼ 23) as well as a strong negative cor-
relation in effect sizes, consistent with the documented
negative correlation between the two traits in population
studies (Figure 2).51 Only rs6136489, a reported eQTL for
SIRPA, showed the same direction of effect for both PLT
and MPV. SIRPA directly interacts with CD47, and SIRPA/
CD47 signaling plays an important role in platelet clear-
ance and the etiology of immune thrombocytopenia pur-
pura.52–54 Knockout Sirpa mice exhibit thrombocytopenia
phenotypes, although they have similar MPV to control50 The American Journal of Human Genetics 99, 40–55, July 7, 2016animals.54 How genetic variation in SIRPA influences
MPV in addition to its demonstrated contribution to PLT
remains to be characterized. In addition to shared associa-
tions of PLT and MPV, there was overlap in the parallel
Exomechip analyses of platelet reactivity. Largely mirror-
ing results from previous GWASs, markers within PEAR1,
JMJD1C, PIK3CG, and MRVI1 showed the strongest associ-
ations with PLT/MPV and platelet reactivity.27,55–57 Other
PLT/MPV-associated markers in PTGES3, LINC00523, and
RASGRP4 showed marginal associations. Notably, PTGES3
is linked to prostaglandin synthesis and the RasGRP family
has been shown to have functional roles in blood cells
including in platelet adhesion.58 The association of
platelet reactivity genes, particularly PEAR1 and MRVI1,
with PLT/MPV further supports a biological relationship
between processes that control platelet function, megakar-
yopoiesis, and clearance.51,59,60 However, these large-scale
association analyses are unable to demonstrate whether
these shared associations indicate shared biological mech-
anisms or simply reflect the epidemiological correlations
among these traits.
In addition to platelet traits, there was substantial over-
lap of genetic associations with RBC andWBC traits exam-
ined by the BCX.18,19 The shared genetic associations with
the two other primary blood cell lineages further supports
other studies proposing that mechanisms that govern
Table 5. Overlap of Associations of Platelet Count and Mean
Platelet Volume Variants with Platelet Reactivity
rsID Gene PLT MPV Agonist(s)a
Direction
of Effectsb
rs12566886 PEAR1 [ Y epi, ADP, collagen YYY
rs10761731 JMJD1C [ Y epi, ADP [[
rs12355784 JMJD1C [ ns epi [
rs342293 PIK3CG Y [ epi Y
rs4909945 MRVI1 ns Y epi, ADP YY
rs2958154 PTGES3 Y [ collagen [
rs12883126 LINC00523 [ ns epi [
rs892055 RASGRP4 [ ns epi Y
Variants were examined using platelet reactivity phenotypes (Table S18) in
GeneSTAR and the Framingham Heart Study (FHS). Arrows denote direction
of effect for platelet count (PLT), mean platelet volume (MPV), and platelet
reactivity (p < 0.001). Multiple arrows refer to direction for respective agonist
for platelet reactivity. Detailed association results for platelet reactivity are
given in Table S19. Abbreviations are as follows: PLT, platelet count; MPV,
mean platelet volume; ns, not significant (p > 0.05); epi, epinephrine.
aPlatelet reactivity associations with p < 0.001.
bCollagen measurements reflect lag time to aggregation, so direction of effect
has been flipped to denote a negative direction of effect as less reactive and
positive direction of effect as more reactive.platelet size and number also influence RBC and WBC
traits.61 In BCX analyses, rs1050331 in the 30 UTR of
ZMIZ2 was associated with increased PLT, mean corpus-
cular hemoglobin (MCH), and mean corpuscular volume
(MCV), as well as with decreased WBC count.18,19
rs1050331 is also an eQTL for ZMIZ2 expression in whole
blood (Table S21).62 There are known sex differences in
cell counts, with females consistently having higher PLT
and mixed results on MPV.63,64 Similar to well-established
PLT- and MPV-associated transcriptional regulator
JMJD1C, ZMIZ2 directly interacts with AR to modulate
AR-mediated transcription and influences mesodermal
development, and thus genetic variation in ZMIZ2 could
potentially contribute to hormonally mediate differences
in PLT across genders.65–67 Also associated with increased
PLT and decreased RBC indices was rs55707100 in
MAP1A.18 Though typically examined in a neurological
context, MAP1A is involved in microtubule assembly, a
process important in blood cell development and func-
tion.68 Our observed association of MAP1A and its expres-
sion in platelets and RBCs suggests that the known role of
MAP1A in developmental and cytoskeletal processes in
neural tissues may extend to blood cells (Table S22). How
these shared genetic factors specifically influence the
development, maintenance, or clearance of multiple blood
cell types remains to be determined.
Overlap with Non-Blood Cell Traits
Although the overlap with other blood cell traits may be
intuitive, we also observed overlap with quantitative lipids
traits. In cross-trait lookups, several known PLT/MPV loci
confirmed in this study (e.g., JMJD1C, GCKR, and SH2B3)
showed associations with lipids traits, and several knownThlipids loci showed association to PLT/MPV (e.g., FADS1,
FADS2, APOH, and TMEM50A). Moreover, SH2B3, which
is also expressed in human vascular endothelial cells where
it modulates inflammation, has been associated with blood
pressure and the risk of MI.69–71 Our study further suggests
that a regulation of platelets could also contribute to po-
tential implication of SH2B3 in the development of cardio-
vascular diseases. The associated SNVs in the FADS1/FADS2
locus (rs174546 and rs174583) are eQTLs for multiple
lipid-related transcripts in blood-related tissues, including
TMEM258, FADS1, FADS2, and LDLR (Table S21).62
Intriguingly, expression of TMEM258 has also been shown
to be a transcriptional regulatory target of cardiovascular
disease implicated CDKN2B-AS1 (MIM: 613149), a
region marginally associated with PLT (discovery EA p ¼
1.00 3 106, replication EA p ¼ 0.0577, combined EA
p ¼ 1.56 3 107) (Table S14).72,73 Our genetic association
results link the underlying genetic architecture of platelet
and lipids traits as suggested by previous epidemiological,
genetic, and animal studies.63,74–77 However, these
observed shared genetic associations do not demonstrate
whether these reflect direct genetic pleiotropy or indirect
relationships. Several variants previously implicated in
lipids (e.g., FADS1, FADS2, SH2B3, TMEM50A, and GCKR)
have stronger associations with lipids traits relative to
our platelet associations, suggesting that their primary ef-
fects are on lipids pathways (Table S20). Determining the
directionality and causality among genetic variants, lipids,
and platelets remains an important future step in dissect-
ing which genetic variants may reveal new insights into
platelet biology.
Conclusions
By performing a large meta-analysis of Exomechip associa-
tion results, we identified rare, low-frequency, and com-
mon variants that influence PLT and MPV. Despite our
ability to detect numerous associations with SNVs across
a wide range of allele frequencies, the Exomechip in-
terrogated a limited fraction of genomic variation.
Sequencing-based studies across the genome in large sam-
ple sizes will be necessary to fully assess the contribution of
variants across the allele frequency spectrum, particularly
of rare variants in intergenic regions. Nonetheless, our
results identify several intriguing genes and genetic mech-
anisms of platelet biology. Many of these associations over-
lapped with related blood cell and lipids traits, pointing to
common mechanisms underlying their development and
maintenance. Because blood cells share developmental lin-
eages and several of our platelet-associated genes have
known developmental or transcriptional regulatory func-
tions, we hypothesize that the origins of these shared ge-
netic associations are mainly in blood cell development
in the bone marrow. How these genes function and
interact in RBC, WBC, and platelet development will
need to be tested in future experiments in both functional
and human-based studies. Advances in these domains
could provide key insights into genes that influencee American Journal of Human Genetics 99, 40–55, July 7, 2016 51
human blood disorders and reveal new mechanisms for
the development of novel therapeutic applications.Supplemental Data
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